Search Results - Gipe, D.A.

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study

    Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study by Gaudet, D, Gipe, D.A, Khoury, É, Pordy, R, Sasiela, W, Chan, K.C

    Published in Atherosclerosis
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS

    ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS by Dufour, R, Stein, E.A, Bergeron, J, Gaudet, D, Weiss, R, Du, Y, Yang, F, Andisik, M, Torri, A, Pordy, R, Gipe, D.A

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Safety, tolerability and pharmacokinetics of evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, in healthy Japanese and Caucasian subjects

    Safety, tolerability and pharmacokinetics of evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, in healthy Japanese and Caucasian subjects by Harada-Shiba, M., Ali, S., Gipe, D.A., Gasparino, E., Son, V., Pordy, R., Catapano, A.L.

    Published in Atherosclerosis
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels

    Evaluating the effect of lipid-apheresis on evinacumab and angiopoietin-like 3 (ANGPTL3) levels by Moriarty, P.M., Dutton, J.-A., Gorby, L., Vance, J., Ali, S., Zhao, A., Khilla, N., Alejandro, M., Rodriguez, J., Rajadhyaksha, M., Andisik, M., Gipe, D.A., Zhang, Y.

    Published in Atherosclerosis
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity

    The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity by Raal, F.J., Rosenson, R.S., Reeskamp, L.F., Kastelein, J.J., Baum, S., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D.A., Pordy, R., Gaudet, D.

    Published in Atherosclerosis
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    5938Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

    5938Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies by Hovingh, G.K., Gipe, D.A., Ahmad, Z., Cuchel, M., Shah, P., Chyu, K.Y., Pordy, R., Sasiela, W.J., Chan, K.C., Khoury, E., Gaudet, D.

    Published in European heart journal
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: